STRATEC SE

Transaction in Own Shares • Jun 30, 2008

News Details

Ad-hoc | 30 June 2008 14:03

STRATEC approves share buyback

STRATEC Biomedical Systems AG / Share Buyback/Share Buyback

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

STRATEC approves share buyback

Birkenfeld, June 30, 2008

The Board of Management of STRATEC Biomedical Systems AG (ISIN
DE0007289001) today approved to acquire treasury stock in the company with
an equivalent value of up to Euro 2.0 million via the stock exchange in the
period from June 30, 2008 to December 31, 2008. STRATEC Biomedical Systems
AG will thus act on the authorization to acquire treasury stock granted by
the Annual General Meeting on May 21, 2008.

It is currently not intended to retire the shares thereby bought back.
STRATEC Biomedical Systems AG will rather obtain the financial scope
necessary to make acquisitions and to safeguard its growth strategy.
Moreover, STRATEC Biomedical Systems AG reserves the right to put the
shares thereby bought back to other uses consistent with the authorization
granted by the Annual General Meeting.

The shares will be exclusively acquired via the Frankfurt Stock Exchange
XETRA trading platform and in each case at current market prices.
No more than 5.319 shares may be acquired on any given stock market trading
day. The execution of the buyback will be managed by a bank which will
decide on the timing of the acquisition of treasury stock independently and
will not be influenced by the company when reaching its decisions.

The company will provide regular information on the progress made with the
share buyback at its internet site at http://www.stratec-biomedical.de.

---

Information and Explaination of the Issuer to this News:

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories, blood banks
and research institutes around the world. The company develops its products
on the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange.

The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in
Germany, the USA, the UK, Switzerland and Romania.

Further information can be obtained from:

STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999
Email: ir@stratec-biomedical.de
30.06.2008 Financial News transmitted by DGAP

---

Language: English
Issuer: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Stuttgart, München, Düsseldorf

End of News DGAP News-Service

---